ICYMI, some of this week’s featured content includes what's trending in skincare for September 2021, and articles about pyschodermatology of acne in adolescents, drug related psoriasis, the link between psoriasis and dementia, plus more.
Lack of specific phenotypes complicates verification.
A new study sheds light on some of the atopic disease risks that are associated with early childhood and continue into midlife.
Skin cancer rates have been increasing worldwide, and climate change factors – like depleting ozone layers – may be a factor.
A recent phase 3 trial investigated the safety of dupilumab as a treatment for severe atopic dermatitis in pediatric patients ages 6 to 11 years.
A survey conducted by Acne Wipeout and OnePoll found that Americans miss out on dating, school, hanging out with friends, and work meetings because of their skin.
A review article investigated the psychological effects acne has on adolescent patients.
A recently published study compared cognition, MRI-markers, and dementia risk in patients diagnosed with psoriasis vs those without psoriasis.
Challenges with overlaps in diagnosis and classification based on rosacea’s 4 subtypes are creating a new focus on features of the condition in each patient. A pipeline of new drugs awaiting FDA approvals could further expand options.
Insight about what to document for these visits.
A patients’ race and cultural background may be a factor in how the hair ages, according to a study in the Journal of Clinical and Aesthetic Dermatology.
Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of September.
Testosterone therapy often leads to unique challenges.
A study in the Journal of Cosmetic Dermatology investigated whether fermented pomegranate extracts can protect against oxidative stress and skin aging.
The National Psoriasis Foundation has released new guidance statements after the Centers for Disease Control and Prevention provided new information on COVID-19 vaccine boosters for immunocompromised patients.